Latest SELLAS Life Sciences News & Updates
See the latest news and media coverage for SELLAS. We track all announcements, press releases, and industry mentions in real time, all in one place.
Late-stage clinical biopharmaceutical company
sellaslifesciences.com- Headquarters
- New York, United States
- Founded year
- 2012
- Company type
- Public company
- Number of employees
- 15–50
Last updated
Latest news about SELLAS Life Sciences (SELLAS)
In short: SELLAS advanced its clinical pipeline, focusing on the Phase 3 REGAL trial and SLS009 studies while managing its financial and regulatory milestones.
Company announcements
-
SELLAS reports Q1 2026 financial results and corporate update
Cash position $107.1M, REGAL trial at 78 events, SLS009 Phase 2 dosing ongoing.
-
SELLAS reports full year 2025 financial results and corporate update
Cash position $71.8M; net loss $26.9M; progress in GPS and SLS009 trials.
-
SELLAS enrolls first patient in first-line AML trial of SLS009
The randomized Phase 2 study will enroll 80 patients unlikely to benefit from standard therapy.
-
SELLAS expands SLS009 clinical program into Europe via IMPACT-AML agreement
The collaboration aims to enable broader U.S. and European patient enrollment for SLS009 in frontline AML.
Media coverage
-
SLS on track to clock best week in over 4 months: Retail divided between stock drop or multibagger status amid upcoming leukemia trial readout
So far this week, SLS has gained nearly 30%, on track for its best week since the week ended Jan 2, if gains hold. ・SELLAS...
-
SELLAS Life Sciences Nears Pivotal Trial Readout As Leukemia Pipeline Progresses
SELLAS Life Sciences Group Inc. (NASDAQ:SLS) reported first-quarter (Q1) 2026 financial results on...
-
SELLAS rises as Q1 update suggests lead program nears final analysis
SELLAS Life Sciences (SLS) added ~16% in extended trading on Wednesday after the cancer drug developer, with its Q1 2026 results, indicated that it will...
-
SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company...
Track SELLAS and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
SELLAS competitors & trending companies
Browse news for competitors to SELLAS and other trending companies.